Together with our partners, we leverage knowledge, experience and insight – enabling us to deploy appropriate financial products for the market, for our partners and ultimately for patients.
Our partnership has reduced the price of 35 million next-generation Interceptor G2 bed nets.
BASFWe are working together to increase access to Interceptor G2 bed nets in malaria-endemic countries.
BMGFMedAccess is a wholly owned subsidiary of CDC Group and forms a key component of the UK development finance institution’s Catalyst Strategies.
CDC GroupOur partnership has reduced the cost of Hologic’s Panther platform for HIV viral load testing by 40-50% in some markets.
CHAIWe partner on strategy and development impact, including working together closely to build our development impact framework.
DalbergMedAccess is a wholly-owned subsidiary of the CDC Group which, in turn, is owned by the Foreign, Commonwealth and Development Office.
FCDOOur agreement with Gavi enables the global vaccine alliance to support continued production of antigen for the RTS,S malaria vaccine by GSK in advance of key policy and funding decisions.
GaviOur innovative finance for market-shaping helps the Global Fund to improve access to HIV, tuberculosis and malaria products.
The Global FundOur partnership with Gavi and GSK supports continued production of antigen for the RTS,S malaria vaccine ahead of key policy and funding decisions.
GSKWe are working together to increase access to viral load testing using the company’s Panther platform. Our partnership has resulted in a $12 ceiling price per patient test.
HologicIVCC is the lead implementer in the New Nets Project, funded by the Global Fund and Unitaid.
IVCCOur volume guarantee is part of a package of measures to increase supply security and availability of Macleods’ 3HP short-course TB preventive therapy.
MacleodsOur volume guarantee will increase access to dual rapid testing for syphilis and HIV.
SD BiosensorFunding provided through UK aid improves access in lower -resource settings to products for infectious diseases such as HIV, TB and malaria by supporting us to enter into new partnerships.
UK aidOur partnership is increasing and accelerating access to vital COVID-19 medical products, including diagnostic tests and clinical management supplies, in low- and middle-income countries.
UNICEF
SIgn up for our quarterly updates to find out more about how our work is making healthcare products more affordable and accessible.
